Please ensure Javascript is enabled for purposes of website accessibility

Syneron Medical Names New CEO

By Eric Volkman - Apr 17, 2013 at 4:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company taps Co-founder and Chairman Shimon Eckhouse to be its new chief executive.

Syneron Medical (ELOS) has put a familiar person on its CEO throne. The company named Shimon Eckhouse as its new chief executive, effective immediately. He succeeds Louis Scafuri, who will "remain available" to the firm through the current quarter to aid in the transition.

Eckhouse is a founder of the company and the chairman of its board. Prior to his tenure at Syneron, he served as CEO at ESC Medical Systems and filled the same role at ColorChip. Syneron director Michael Anghel said, "[Eckhouse] has a deep understanding of the Company's strategy, management team, business potential and industry trends."

Scafuri had been CEO since Feb. 2009.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Syneron Medical Ltd. Stock Quote
Syneron Medical Ltd.
ELOS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.